Jefferies Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Jefferies Group’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-667	Closed	-$25K	–	1683
2020 Q4	$25K	Buy	+667	New	+$24.9K	﹤0.01%	1514

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jefferies Group's CRBP Position: Q1 2021 in Review

Jefferies Group sold out of Corbus Pharmaceuticals (CRBP) in Q1 2021, closing a stake of 667 shares — an estimated $25K sold.

Jefferies Group first reported a position in CRBP in Q4 2020 and held it in 1 quarter. The position peaked at $25K in Q4 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2021.

Jefferies Group reported no remaining Corbus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 667 Corbus Pharmaceuticals shares in Q1 2021, an estimated $25K.
Jefferies Group first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Jefferies Group's Corbus Pharmaceuticals position peaked at $25K in Q4 2020.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.